The biotechnology company, founded in 2019 and based in Waltham, Massachusetts, specializes in discovering and developing antibody therapeutics that target enzyme hyperactivity caused by overactive extracellular proteases, which trigger tissue damage and broad inflammatory responses. Amagma's therapies offer a safe and effective treatment option for inflammatory diseases, particularly GI disorders, that have been difficult to treat with other approaches. The company is backed by private investors, including Polaris Partners, and led by experienced entrepreneurs such as Prof. Tillman Gerngross and Prof. Leonard Zon.